REGN

Regeneron Pharmaceuticals has rallied hard in recent years, and with the stock around US$928.61 after a sharp climb, the real question is whether that share price still lines up with the earnings power investors are paying for.

Regeneron Pharmaceuticals reported third quarter 2026 revenue of US$5,115.8 million and net income of US$1,948.7 million, alongside a quarterly dividend of US$0.94 per share and ongoing share repurchases under its April 2026 buyback program.

An early-stage liver disease therapy cut fat by 70% in just 12 weeks, signaling the genetics engine's potential to fuel growth beyond current blockbusters.

Regeneron rallied to a two-year high as Dupixent drives strong Q3 earnings. But is there any further upside left in REGN shares? Let’s find out!

Regeneron Pharmaceuticals (REGN) moved sharply after reporting third quarter 2026 results, with revenue of US$5.12b and net income of US$1.95b, along with stronger non GAAP earnings and record contributions from Dupixent, EYLEA HD and Libtayo.

Shares of biotech company Regeneron (NASDAQ:REGN) jumped 11.5% in the afternoon session after the company reported a 36% increase in third-quarter 2026 revenue to $5.1 billion, alongside a 70% rise in non-GAAP diluted earnings per share to $20.07.

Regeneron's Q3 earnings and revenues beat estimates, fueled by strong Dupixent profits, Eylea HD growth and robust Libtayo demand. Stock up.

Regeneron stock jumped to a two-year high Friday after its Sanofi-partnered inflammation giant, Dupixent, handily beat expectations.

Regeneron (NASDAQ:REGN) shares rose 13.55% in Friday’s session, trading at $929.69 as of 9:45 AM ET on Oct 30, 2026. For a biotech worth roughly $94.03 billion, a double-digit move matters for more than its own shareholders.

Key TakeawaysRegeneron shares jumped 12% after third-quarter revenue rose 36% to $5. 1 billion.